These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 35996883)

  • 1. Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.
    Li T; Hiemstra IH; Chiu C; Oliveri RS; Elliott B; DeMarco D; Salcedo T; Egerod FL; Sasser K; Ahmadi T; Gupta M
    Clin Pharmacol Ther; 2022 Nov; 112(5):1108-1119. PubMed ID: 35996883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
    Takaura K; Ando H; Ganoza ER
    Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
    Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
    Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
    Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
    Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
    [No Abstract]   [Full Text] [Related]  

  • 6. Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas.
    Falchi L; Rahman J; Melendez L; Douglas M; Amador WR; Hamlin P; Kumar A; Hoehn D; Lin YH; Gao Q; Roshal M; Ewalt MD; Dogan A; Greenbaum B; Salles GA; Vardhana SA
    medRxiv; 2024 Jul; ():. PubMed ID: 39006439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor.
    Guo C; Liao KH; Li M; Wang IM; Shaik N; Yin D
    CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1619-1625. PubMed ID: 36394153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities.
    Niu J; Wang W; Ouellet D
    Expert Rev Clin Pharmacol; 2023; 16(10):977-990. PubMed ID: 37743720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation of the efficacy of antibody-drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88.
    Li Q; Wang L; Zhang J; Zhao G; Liu Z; Ma X; Jiang J
    Clin Transl Sci; 2023 Jul; 16(7):1232-1242. PubMed ID: 37259689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epcoritamab, a promising therapy for Richter syndrome?
    Kater A
    Clin Adv Hematol Oncol; 2024 Mar; 22(2):90-91. PubMed ID: 38446476
    [No Abstract]   [Full Text] [Related]  

  • 11. Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy.
    Schropp J; Khot A; Shah DK; Koch G
    CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):177-187. PubMed ID: 30480383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule.
    Hosseini I; Fleisher B; Getz J; Decalf J; Kwong M; Ovacik M; Bainbridge TW; Moussion C; Rao GK; Gadkar K; Kamath AV; Ramanujan S
    Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging pharmacokinetic parameters as covariate in Bayesian logistic regression model to optimize dose selection in early phase oncology trial.
    Wei X; Li X; Guo Z
    J Biopharm Stat; 2024 Jul; ():1-22. PubMed ID: 39028254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab.
    Yoshida K; Poon V; Dash A; Kunder R; Chinn L; Kågedal M
    CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):544-550. PubMed ID: 38343040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.
    Riaz R; Khan A; Siddiqui T
    Rare Tumors; 2023; 15():20363613231193566. PubMed ID: 37534337
    [No Abstract]   [Full Text] [Related]  

  • 16. Epcoritamab-bysp.
    Am J Health Syst Pharm; 2023 Sep; 80(19):1289-1292. PubMed ID: 37471178
    [No Abstract]   [Full Text] [Related]  

  • 17. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL).
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e103-e104. PubMed ID: 37339097
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
    Mhibik M; Gaglione EM; Eik D; Herrick J; Le J; Ahn IE; Chiu C; Wielgos-Bonvallet M; Hiemstra IH; Breij ECW; Chen J; Reilly EB; Epling-Burnette PK; Szafer-Glusman E; Sun C; Wiestner A
    Blood Adv; 2023 Aug; 7(15):4089-4101. PubMed ID: 37219524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.